Verily Secures $300 Million Investment to Advance its Precision Health AI Strategy.
Published: 01 Apr 2026
Author: Precedence Research
UCHealth, the University of Colorado Anschutz, and other investors want to advance the next phase of its precision health AI strategy with participation from Alphabet. Verily has announced a $300 million investment round led by Series X Capital. With this funding, Alphabet will be a significant minority investor in Verily, while no longer having a controlling stake.
Chairman and CEO of Verily, Stephen Gillett, said This announcement is an important step in our mission to bring the promise of precision health to everyone. End-to-end solution from research to care, our customers need solutions that bring the best of clinical and scientific expertise together with AI to deliver the next generation of healthcare - one that is as precise as it is personal.
The market is driven by power AI-enabled precision health solutions.
According to Towards Healthcare, the Digital Health and AI market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 389.91 billion in 2026 to approximately USD 2300.31 billion by 2035, representing a compound annual growth rate (CAGR) of 21.8% from 2026 to 2035. Market growth is driven by increasing pharmaceutical outsourcing, rising demand for generics and biologics, cost optimization pressures, technological advancements, expanding clinical pipelines, and supportive regulatory frameworks across emerging and developed regions globally.
Verily Partnership and Collaboration
Verily has many commercial partnerships, a new collaboration with Samsung’s Galaxy Watch helps life sciences customers accelerate clinical research through biomarker development on the Pre-platform, and a strategic partnership with Salesforce. This announcement of the integration of the Verily Pre-Platform with Agentforce Health to power enterprise precision health solutions. This announcement was built on recent collaboration with UCHealth, the University of Colorado Anschutz, and RefinedScience with the Verily Pre-platform for AI-powered research and care transformation.
Founder and Managing Partner of Series X Capital, Gideon Yu, said Series X Capital was established in collaboration with Google’s X, The Moonshot Factory, to scale moonshot technologies into consequential, world-changing companies. We are extremely excited to lead this milestone round for Verily, as they drive commercial momentum as a leader in precision health.
About Verily Health Inc.
Verily is a data platform and technology company. Its purpose is to build power AI-enabled precision health solutions that accelerate research and improve care for individuals and communities. It is positioned at the intersection of technology, data science, and healthcare. It transforms multimodal health data into insights, models, and actions that make healthcare more personalised.
A recent report by Towards Healthcare highlights that the Digital Health and AI Market is driven by increasing adoption of telehealth, AI diagnostics, data analytics, and growing demand for personalized healthcare solutions.